VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, today announced it has entered into a collaboration with the University of California, Los Angeles through Dennis J. Slamon, M.D., Ph.D., to explore potential clinical indications in breast cancer for a number of Zymeworks’ bi-specific antibodies.
“We’re very excited to work with Dr. Slamon and his group in the investigation of our Azymetric™ bi-specific antibodies against breast cancer and other malignancies,” says Dr. Ali Tehrani, President and CEO of Zymeworks. “Dr. Slamon is a world leader in the field of HER2-positive breast cancer, and we are confident this collaboration will likely help propel Zymeworks’ oncology franchise towards human clinical trials with multiple INDs beginning in 2016.”
About Zymeworks Inc.
Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. The company’s novel Azymetric™ and AlbuCORE™ platforms, and its proprietary ZymeCAD™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. More information on Zymeworks can be found at www.zymeworks.com.
About Dr. Dennis Slamon and UCLA
Dennis J. Slamon, M.D., Ph.D., serves as director of Clinical/Translational Research, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Slamon also serves as director of the medical advisory board for the National Colorectal Cancer Research Alliance, a fund-raising organization that promotes advances in colorectal cancer.